OBJECTIVES: Patterns of growth following highly active antiretroviral therapy (HAART) administration among children are not well defined. The objective of this study was to determine rates and predictors of growth reconstitution among children on HAART. METHODS: A study was conducted among HIV-1-infected children initiating HAART at an HIV treatment clinic in Kenya. Kaplan-Meier survival curves and Cox proportional hazards regression models compared catch-up growth (Z-score ≥ 0) at 12 months post-HAART. Multivariate linear mixed-effects models determined rates and predictors of growth following HAART. RESULTS: One hundred and seventy-three HIV-1-infected children initiated HAART with a median age of 4.7 years [interquartile range (IQR) 2.4, 7.0]. At baseline, children below 3 years had lower weight-for-age (WAZ) and weight-for-height (WHZ) Z-scores than children 3-5 and 6-10 years (WAZ: P = 0.03; WHZ: P = 0.006). Adjusting for baseline growth, children below 3 years were two to three-fold more likely to attain population age-norms (Z-score = 0) than 6-10 years (WAZ: P = 0.055; WHZ: P = 0.005) at 12 months post-HAART. After adjustment, children below 3 years had higher increases in WAZ and WHZ following HAART than 6-10 years (WAZ: P = 0.006; WHZ: P = 0.005). Children at WHO stage at least 3 at baseline experienced more rapid WHZ reconstitution (P = 0.002). Food supplementation while on HAART was associated with increased monthly gains in weight indices (WAZ: P = 0.001; WHZ: P = 0.005), and multivitamins were associated with greater increases in height (P < 0.01). CONCLUSION: Following HAART initiation, younger children had more rapid catch-up to the population-average weight of their peers than older children, demonstrating growth benefit of earlier HAART. In addition to HAART, food supplementation and multivitamins may also accelerate growth reconstitution.
OBJECTIVES: Patterns of growth following highly active antiretroviral therapy (HAART) administration among children are not well defined. The objective of this study was to determine rates and predictors of growth reconstitution among children on HAART. METHODS: A study was conducted among HIV-1-infectedchildren initiating HAART at an HIV treatment clinic in Kenya. Kaplan-Meier survival curves and Cox proportional hazards regression models compared catch-up growth (Z-score ≥ 0) at 12 months post-HAART. Multivariate linear mixed-effects models determined rates and predictors of growth following HAART. RESULTS: One hundred and seventy-three HIV-1-infectedchildren initiated HAART with a median age of 4.7 years [interquartile range (IQR) 2.4, 7.0]. At baseline, children below 3 years had lower weight-for-age (WAZ) and weight-for-height (WHZ) Z-scores than children 3-5 and 6-10 years (WAZ: P = 0.03; WHZ: P = 0.006). Adjusting for baseline growth, children below 3 years were two to three-fold more likely to attain population age-norms (Z-score = 0) than 6-10 years (WAZ: P = 0.055; WHZ: P = 0.005) at 12 months post-HAART. After adjustment, children below 3 years had higher increases in WAZ and WHZ following HAART than 6-10 years (WAZ: P = 0.006; WHZ: P = 0.005). Children at WHO stage at least 3 at baseline experienced more rapid WHZ reconstitution (P = 0.002). Food supplementation while on HAART was associated with increased monthly gains in weight indices (WAZ: P = 0.001; WHZ: P = 0.005), and multivitamins were associated with greater increases in height (P < 0.01). CONCLUSION: Following HAART initiation, younger children had more rapid catch-up to the population-average weight of their peers than older children, demonstrating growth benefit of earlier HAART. In addition to HAART, food supplementation and multivitamins may also accelerate growth reconstitution.
Authors: Stephen M Arpadi; Mary Horlick; John Thornton; Patricia A Cuff; Jack Wang; Donald P Kotler Journal: J Acquir Immune Defic Syndr Date: 2002-04-15 Impact factor: 3.731
Authors: Gwenda Verweel; Annemarie M C van Rossum; Nico G Hartwig; Tom F W Wolfs; Henriëtte J Scherpbier; Ronald de Groot Journal: Pediatrics Date: 2002-02 Impact factor: 7.124
Authors: F Steiner; C Kind; C Aebi; C A Wyler-Lazarevitch; J J Cheseaux; C Rudin; L Molinari; D Nadal Journal: Eur J Pediatr Date: 2001-10 Impact factor: 3.183
Authors: J C Lindsey; M D Hughes; R E McKinney; M K Cowles; J A Englund; C J Baker; S K Burchett; M W Kline; A Kovacs; J Moye Journal: J Infect Dis Date: 2000-09-22 Impact factor: 5.226
Authors: Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller Journal: Am J Clin Nutr Date: 2011-11-02 Impact factor: 7.045
Authors: Anjuli D Wagner; Cyrus Mugo; Irene N Njuguna; Elizabeth Maleche-Obimbo; Kenneth Sherr; Irene W Inwani; James P Hughes; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731
Authors: Ramadhani S Mwiru; Donna Spiegelman; Christopher Duggan; George R Seage; Helen Semu; Guerino Chalamilla; Rodrick Kisenge; Wafaie W Fawzi Journal: J Trop Pediatr Date: 2014-01-06 Impact factor: 1.165
Authors: Anjuli D Wagner; Gabrielle OʼMalley; Olivia Firdawsi; Cyrus Mugo; Irene N Njuguna; Elizabeth Maleche-Obimbo; Irene W Inwani; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Thomas Gsponer; Ralf Weigel; Mary-Ann Davies; Carolyn Bolton; Harry Moultrie; Paula Vaz; Helena Rabie; Karl Technau; James Ndirangu; Brian Eley; Daniela Garone; Maureen Wellington; Janet Giddy; Jochen Ehmer; Matthias Egger; Olivia Keiser Journal: Pediatrics Date: 2012-09-17 Impact factor: 7.124
Authors: Paige L Williams; Mark J Abzug; Denise L Jacobson; Jiajia Wang; Russell B Van Dyke; Rohan Hazra; Kunjal Patel; Linda A Dimeglio; Elizabeth J McFarland; Margarita Silio; William Borkowsky; George R Seage; James M Oleske; Mitchell E Geffner Journal: AIDS Date: 2013-07-31 Impact factor: 4.177